Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Danny Rischin, MD, on Cutaneous Squamous Cell Carcinoma: Follow-up Data on Cemiplimab

Posted: Tuesday, July 7, 2020

Danny Rischin, MD, of the Peter MacCallum Cancer Centre, discusses phase II study results showing that, for patients with advanced cutaneous squamous cell carcinoma, cemiplimab achieves overall response rates, duration of response, and survival superior to what has been reported with other agents.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.